PE20170184A1 - Derivados de piperidina como antagonista de receptores de orexina - Google Patents

Derivados de piperidina como antagonista de receptores de orexina

Info

Publication number
PE20170184A1
PE20170184A1 PE2016001578A PE2016001578A PE20170184A1 PE 20170184 A1 PE20170184 A1 PE 20170184A1 PE 2016001578 A PE2016001578 A PE 2016001578A PE 2016001578 A PE2016001578 A PE 2016001578A PE 20170184 A1 PE20170184 A1 PE 20170184A1
Authority
PE
Peru
Prior art keywords
optionally substituted
substituted
orexin receptors
antagonist
compounds
Prior art date
Application number
PE2016001578A
Other languages
English (en)
Inventor
Shuhui Chen
Yuan Chen
Haiying He
Jiong Lan
Yang Zhang
Qiang Lv
Biao Ma
Yuhe Wang
Songliang Wu
Xing Liu
Original Assignee
Shanghai Haiyan Pharmaceutical Tech Co Ltd
Yangtze River Pharm Group Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54054589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai Haiyan Pharmaceutical Tech Co Ltd, Yangtze River Pharm Group Co filed Critical Shanghai Haiyan Pharmaceutical Tech Co Ltd
Publication of PE20170184A1 publication Critical patent/PE20170184A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINA DE FORMULA (I) DONDE A ES UN CICLOHIDROCARBILO, HETEROCICLOHIDROCARBILO O HETEROHIDROCARBILO CICLICO DE 3 A 12 MIEMBROS OPCIONALMENTE SUSTITUIDO; B ES C(=O), S(=O) O S(=O)2; X ES (CH2)r1(U)r2(CH2)r3 OPCIONALMENTE SUSTITUIDO, EN DONDE U ES HALOGENO, HIDROXI, ALQUILO C1-6, ENTRE OTROS; D Y L SON CADA UNO CH2 OPCIONALMENTE SUSTITUIDO CON F, Br, CN, ENTRE OTROS; T ES C O UN ENLACE; CUANDO M ES C(Y)(R1a) Q ES C(R1b)(R1c) Y VICEVERSA, EN DONDE Y ES (CH2)r4(G)r5(CH2)r6-Y1; Y1 es O-E, ENTRE OTROS, EN DONDE E ES CICLOHIDROCARBILO O HETEROCICLO DE 5 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; G ES HALOGENO SUSTITUIDO, HIDROXI SUSTITUIDO, ENTRE OTROS; r1, r3, r4 y r6 SON DE 0 A 2; r2 y r5 SON 0 O 1; R1a, R1b, R1c, R2 y R3 SON CADA UNO H, F, CN, NH2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS LOS DE FORMULA (i), (ii), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE RECEPTORES DE OREXINA SIENDO UTILES EN EL TRATAMIENTO DE INSOMNIO, ANSIEDAD, TRASTORNO OBSESIVO-COMPULSIVO
PE2016001578A 2014-03-06 2015-02-27 Derivados de piperidina como antagonista de receptores de orexina PE20170184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410081220 2014-03-06

Publications (1)

Publication Number Publication Date
PE20170184A1 true PE20170184A1 (es) 2017-04-07

Family

ID=54054589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001578A PE20170184A1 (es) 2014-03-06 2015-02-27 Derivados de piperidina como antagonista de receptores de orexina

Country Status (16)

Country Link
US (1) US10100047B2 (es)
EP (1) EP3115362B1 (es)
JP (1) JP6262885B2 (es)
KR (1) KR101920472B1 (es)
CN (1) CN106414439B (es)
AU (1) AU2015226679B2 (es)
CA (1) CA2941663C (es)
CL (1) CL2016002240A1 (es)
IL (1) IL247584A0 (es)
MX (1) MX2016011549A (es)
NZ (1) NZ723671A (es)
PE (1) PE20170184A1 (es)
RU (1) RU2669701C2 (es)
SG (2) SG11201607183PA (es)
WO (1) WO2015131773A1 (es)
ZA (1) ZA201606141B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
WO2017028732A1 (zh) 2015-08-14 2017-02-23 上海海雁医药科技有限公司 食欲素受体拮抗剂化合物的晶型及其制备方法和应用
SG11201804223TA (en) 2015-11-23 2018-06-28 Sunshine Lake Pharma Co Ltd OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
EP4438041A3 (en) 2016-02-04 2025-01-01 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
EP4137124B1 (en) * 2020-04-17 2026-02-25 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Solid pharmaceutical preparation, preparation method therefor and use thereof
CN112480107B (zh) * 2020-11-30 2022-08-16 上海海雁医药科技有限公司 取代的氮杂双环辛烷化合物及其中间体和制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401328T1 (de) * 2003-05-13 2008-08-15 Schering Corp Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren
EP2056828A4 (en) * 2006-08-21 2010-06-23 Merck Sharp & Dohme SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS
JP2010527924A (ja) * 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
WO2008147518A1 (en) * 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
US8030495B2 (en) * 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
US8188280B2 (en) * 2008-02-06 2012-05-29 Msd K.K. 3-substituted sulfonyl piperidine derivative
BRPI0908096A2 (pt) * 2008-02-21 2015-08-25 Actelion Pharmaceuticals Ltd Derivado de 2-aza-biciclo [2.2.1] heptano
JP2012506375A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
WO2010048016A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
AU2009307918A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
CA2739915A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
ES2543692T3 (es) * 2010-04-29 2015-08-21 The University Of Edinburgh (8-aza-biciclo[3.2.1biciclo[oct-8-il)-[5-(1H-pirazol-4-il)-tiofeno-3-il]-metanonas 3,3-disustituidas como inhibidores de 11beta-HSD1
KR101764952B1 (ko) * 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
JPWO2013005755A1 (ja) * 2011-07-05 2015-02-23 大正製薬株式会社 メチルピペリジン誘導体
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP2752410B1 (en) * 2011-10-25 2016-08-31 Shionogi & Co., Ltd. Heterocycle derivative having pgd2 receptor antagonist activity
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
MX2015006191A (es) 2012-11-16 2015-08-10 Merck Sharp & Dohme Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途

Also Published As

Publication number Publication date
EP3115362A4 (en) 2017-08-16
IL247584A0 (en) 2016-11-30
US20170233385A1 (en) 2017-08-17
US10100047B2 (en) 2018-10-16
JP2017507185A (ja) 2017-03-16
KR101920472B1 (ko) 2019-02-08
CN106414439A (zh) 2017-02-15
KR20160143668A (ko) 2016-12-14
NZ723671A (en) 2017-05-26
ZA201606141B (en) 2017-05-31
EP3115362B1 (en) 2019-06-12
CA2941663A1 (en) 2015-09-11
WO2015131773A1 (zh) 2015-09-11
CL2016002240A1 (es) 2017-02-17
SG11201607183PA (en) 2016-10-28
AU2015226679A1 (en) 2016-09-15
SG10201900536TA (en) 2019-02-27
CA2941663C (en) 2020-02-18
RU2016130937A (ru) 2018-04-09
JP6262885B2 (ja) 2018-01-17
EP3115362A1 (en) 2017-01-11
RU2669701C2 (ru) 2018-10-15
MX2016011549A (es) 2017-05-08
CN106414439B (zh) 2017-12-08
AU2015226679B2 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
CL2022000558A1 (es) Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip (divisional 2 solicitud 202002033)
PE20160431A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CL2017002452A1 (es) Nuevos compuestos bicíclicos
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
MX385424B (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
EP3654978A4 (en) HETEROCYCLIC COMPOUNDS USED AS ADENOSINE ANTAGONISTS
PE20171306A1 (es) Derivados de quinazolina utilizados para tratar el vih
AR099677A1 (es) Compuesto heterocíclico fusionado y su uso para el control de plagas
PE20190509A1 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
MX2018000880A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
EA201590092A1 (ru) АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
AR100154A1 (es) Compuesto heterocíclico que contiene nitrógeno
CL2015002609A1 (es) 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina.
PE20170144A1 (es) 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet
PE20161572A1 (es) Compuestos como moduladores de ror gamma
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
MX387238B (es) Procesos e compuestos intermedios en la preparación de antagonistas de c5ar.
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα

Legal Events

Date Code Title Description
FD Application declared void or lapsed